AlphaVax, Inc. will hold its annual Institutional Biosafety Committee (IBC) Meeting on Friday, June 12th, 2009, at 12 noon. The meeting, which is open to the public, will be held at AlphaVax, Inc.’s corporate offices located at 2 Triangle Drive, Research Triangle Park, NC 27709. If you wish to attend, or would like further information, please contact Alison Worley (919) 595-0321.

AlphaVax announced today the completion of enrollment in a Phase I/II cancer immunotherapy study being conducted by the Duke University Comprehensive Cancer Center, Durham, NC. This is an open-label, dose-escalation study to evaluate the safety and immunogenicity of carcinoembryonic antigen (CEA(6D))-expressing virus-like replicon particle (VRP) immunotherapy in patients with advanced or metastatic CEA-expressing malignancies.

Novartis enters into exclusive agreement with AlphaVax for novel CMV vaccine candidate Novartis announced on December 29, 2008 an exclusive agreement to license AlphaVax' CMV vaccine candidate. Cytomegalovirus (CMV) infects approximately 86,000 newborns in the US and EU each year, causing 700 deaths and 17,500 cases of severe disability. Novartis expects to initiate Phase II clinical trials of this vaccine in 2009.